KIR2DL3/CD158b2 Antibody (GL183)
Novus Biologicals, part of Bio-Techne | Catalog # NB100-65875
Key Product Details
Species Reactivity
Human
Applications
Flow Cytometry, Immunoprecipitation
Label
Unconjugated
Antibody Source
Monoclonal Mouse IgG1 Clone # GL183
Concentration
1 mg/ml
Product Specifications
Immunogen
NK cell clone E57
Specificity
NB100-65875 recognizes the human CD158b cell surface antigen, a 58kD glycoprotein expressed by a subset of NK cells (also known as p58.2 antigen). This antibody also recognizes a 50kD molecule, which is highly homologous to p58.2 in the extracellular domain, but has a shorter cytoplasmic tail. Both molecules are members of the newly described natural killer cell receptor family. CD158b functions as a receptor specific for HLA Class I molecules, including Cw3 and related HLA-C alleles. This antibody can restore the lysis by human NK clones of otherwise lysis protected targets expressing Cw3.
Clonality
Monoclonal
Host
Mouse
Isotype
IgG1
Applications for KIR2DL3/CD158b2 Antibody (GL183)
Application
Recommended Usage
Flow Cytometry
1:10-1:50
Immunoprecipitation
1:10-1:500
Formulation, Preparation, and Storage
Purification
Protein A or G purified
Formulation
PBS
Preservative
0.09% Sodium Azide
Concentration
1 mg/ml
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Background: KIR2DL3/CD158b2
Long Name
Killer Cell Immunoglobulin-like Receptor, Two Domain Long Cytoplasmic Tail, 3
Alternate Names
CD158b2, NKAT2
Entrez Gene IDs
3804 (Human)
Gene Symbol
KIR2DL3
UniProt
Additional KIR2DL3/CD158b2 Products
Product Documents for KIR2DL3/CD158b2 Antibody (GL183)
Product Specific Notices for KIR2DL3/CD158b2 Antibody (GL183)
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...